Clinical Trial Update: Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a phase 1/2 clinical trial of lenalidomide in relapse/refractory Waldenstrom macroglobulinemia, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenstrom Macroglobulinemia

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: University Hospital, Lille | Conditions: Waldenstrom Macroglobulinemia | Phase 1, Phase 2 | Status: COMPLETED